Zacks Investment Research upgraded shares of NantHealth (NASDAQ:NH) from a hold rating to a buy rating in a report published on Friday morning, Zacks.com reports. The firm currently has $0.75 price objective on the stock.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
NH stock opened at $0.60 on Friday. The company has a quick ratio of 0.86, a current ratio of 0.87 and a debt-to-equity ratio of 70.81. The company has a market capitalization of $66.44 million, a PE ratio of -0.35 and a beta of 1.15. NantHealth has a 1 year low of $0.48 and a 1 year high of $3.64.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paloma Partners Management Co acquired a new stake in shares of NantHealth in the fourth quarter valued at $31,000. SG Americas Securities LLC acquired a new stake in shares of NantHealth in the fourth quarter valued at $29,000. Finally, Miracle Mile Advisors LLC acquired a new stake in shares of NantHealth in the first quarter valued at $27,000. Institutional investors and hedge funds own 4.68% of the company’s stock.
NantHealth, Inc, together with its subsidiaries, operates as a healthcare technology company in the United States and internationally. The company engages in converging science and technology through an integrated clinical platform to provide health information at the point of care. It develops NantHealth solutions, including molecular profiling solutions, software, and hardware systems infrastructure, which integrates patient data management, bioinformatics, and molecular medicine to enable value-based care and evidence-based clinical practice.
Further Reading: How interest rates affect municipal bond prices
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.